D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
August 11, 2021 at 02:30 am EDT
Share
D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the year ending December 31, 2021. For the period, the company expects net sales to be of JPY 340 million. Operating loss expected to be of JPY 580 million. Loss attributable to owners of the parent expected to be of JPY 530 million. Loss per share expected to be of JPY 18.12.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
